Skip to main content
SpringerLink
Log in
Book cover

Hyperlipidemia in Primary Care pp 205–218Cite as

Treatment of Dyslipidemia in Patients with Renal Insufficiency and End-Stage Renal Disease

  • Chapter
  • First Online:

  • 794 Accesses

Part of the book series: Current Clinical Practice ((CCP))

Abstract

A 54-year-old African American male patient comes to the office for a preoperative assessment prior to the placement of an A-V fistula for hemodialysis. He was recently diagnosed with end-stage renal disease and started on hemodialysis through a temporary catheter. He has a long standing history of hypertension which has been poorly controlled due in part to lack of compliance with medications because of side effects. In the office, he has no complaints except for fatigue and pain in his legs when he walks. He has no chest pain. There is no history of prior cardiac disease or diabetes.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–266.

    Google Scholar 

  2. Shulman NB, Ford CE, Hall WD, et al. Prognostic value of serum creatinine and effect of ­treatment of hypertension on renal function. Results from the hypertension detection and ­follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension. 1989;13(5 Suppl):I80–93.

    PubMed  CAS  Google Scholar 

  3. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis. 1998;32(5):853–906.

    Article  PubMed  CAS  Google Scholar 

  4. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61(5):1887–93.

    Article  PubMed  Google Scholar 

  5. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003;42(5):1050–65.

    Article  PubMed  CAS  Google Scholar 

  6. Uhlig K, Levey AS, Sarnak MJ. Traditional cardiac risk factors in individuals with chronic kidney disease. Semin Dial. 2003;16(2):118–27.

    Article  PubMed  Google Scholar 

  7. Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S142–56.

    Article  PubMed  CAS  Google Scholar 

  8. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep. 2000;2(3):200–7.

    Article  PubMed  CAS  Google Scholar 

  9. Roheim PS, Asztalos BF. Clinical significance of lipoprotein size and risk for coronary atherosclerosis. Clin Chem. 1995;41(1):147–52.

    PubMed  CAS  Google Scholar 

  10. Shearer GC, Stevenson FT, Atkinson DN, Jones H, Staprans I, Kaysen GA. Hypoalbuminemia and proteinuria contribute separately to reduced lipoprotein catabolism in the nephrotic ­syndrome. Kidney Int. 2001;59(1):179–89.

    Article  PubMed  CAS  Google Scholar 

  11. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential ­consequences. Am J Physiol Renal Physiol. 2006;290(2):F262–72.

    Article  PubMed  CAS  Google Scholar 

  12. Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14(6):1462–6.

    Article  PubMed  CAS  Google Scholar 

  13. Vaziri ND, Moradi H. Mechanisms of dyslipidemia of chronic renal failure. Hemodial Int. 2006;10(1):1–7.

    Article  PubMed  Google Scholar 

  14. Holdaas H. Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy? Am J Cardiovasc Drugs. 2005;5(4):255–69.

    Article  PubMed  CAS  Google Scholar 

  15. Jones CA, Francis ME, Eberhardt MS, et al. Microalbuminuria in the US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002;39(3):445–59.

    Article  PubMed  Google Scholar 

  16. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J. 1984;108(5):1347–52.

    Article  PubMed  CAS  Google Scholar 

  17. Romundstad S, Holmen J, Kvenild K, Hallan H, Ellekjaer H. Microalbuminuria and all-cause mortality in 2,089 apparently healthy individuals: a 4.4-year follow-up study. The Nord-Trondelag Health Study (HUNT), Norway. Am J Kidney Dis. 2003;42(3):466–73.

    Article  PubMed  Google Scholar 

  18. Wachtell K, Olsen MH, Dahlof B, et al. Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. J Hypertens. 2002;20(3):405–12.

    Article  PubMed  CAS  Google Scholar 

  19. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003;139(11):901–6.

    PubMed  Google Scholar 

  20. Hillege HL, Fidler V, Diercks GF, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106(14):1777–82.

    Article  PubMed  CAS  Google Scholar 

  21. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–6.

    Article  PubMed  CAS  Google Scholar 

  22. Clausen P, Jensen JS, Jensen G, Borch-Johnsen K, Feldt-Rasmussen B. Elevated urinary albumin excretion is associated with impaired arterial dilatory capacity in clinically healthy subjects. Circulation. 2001;103(14):1869–74.

    PubMed  CAS  Google Scholar 

  23. Schaeffner ES, Kurth T, Curhan GC, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14(8):2084–91.

    PubMed  CAS  Google Scholar 

  24. Yerkey MW, Kernis SJ, Franklin BA, Sandberg KR, McCullough PA. Renal dysfunction and acceleration of coronary disease. Heart. 2004;90(8):961–6.

    Article  PubMed  CAS  Google Scholar 

  25. Sahadevan M, Kasiske BL. Hyperlipidemia in kidney disease: causes and consequences. Curr Opin Nephrol Hypertens. 2002;11(3):323–9.

    Article  PubMed  Google Scholar 

  26. Ruan XZ, Varghese Z, Powis SH, Moorhead JF. Dysregulation of LDL receptor under the influence of inflammatory cytokines: a new pathway for foam cell formation. Kidney Int. 2001;60(5):1716–25.

    Article  PubMed  CAS  Google Scholar 

  27. Kasiske BL, O’Donnell MP, Cleary MP, Keane WF. Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 1988;33(3):667–72.

    Article  PubMed  CAS  Google Scholar 

  28. Vazquez-Perez S, Aragoncillo P, de Las HN, et al. Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolaemic rabbits. Nephrol Dial Transplant. 2001;16 Suppl 1:40–4.

    PubMed  CAS  Google Scholar 

  29. Vaziri ND, Liang K. ACAT inhibition reverses LCAT deficiency and improves plasma HDL in chronic renal failure. Am J Physiol Renal Physiol. 2004;287(5):F1038–43.

    Article  PubMed  CAS  Google Scholar 

  30. Kasiske BL, Crosson JT. Renal disease in patients with massive obesity. Arch Intern Med. 1986;146(6):1105–9.

    Article  PubMed  CAS  Google Scholar 

  31. Manttari M, Tiula E, Alikoski T, Manninen V. Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension. 1995;26(4):670–5.

    PubMed  CAS  Google Scholar 

  32. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH. Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ. 1997;314(7083):783–8.

    PubMed  CAS  Google Scholar 

  33. Kohler KA, McClellan WM, Ziemer DC, Kleinbaum DG, Boring JR. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. Am J Kidney Dis. 2000;36(5):903–13.

    Article  PubMed  CAS  Google Scholar 

  34. Bash LD, Astor BC, Coresh J. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2010;55(1):31–41.

    Article  PubMed  Google Scholar 

  35. Douglas K, O’Malley PG, Jackson JL. Meta-analysis: the effect of statins on albuminuria. Ann Intern Med. 2006;145(2):117–24.

    PubMed  CAS  Google Scholar 

  36. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal ­function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol. 2003;14(6):1605–13.

    Article  PubMed  CAS  Google Scholar 

  37. Strippoli GF, Navaneethan SD, Johnson DW, et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ. 2008;336(7645):645–51.

    Article  PubMed  CAS  Google Scholar 

  38. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation. 2004;110(18):2809–16.

    Article  PubMed  CAS  Google Scholar 

  39. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.

    Article  Google Scholar 

  40. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53(5):741–50.

    Article  PubMed  CAS  Google Scholar 

  41. Shepherd J, Kastelein JP, Bittner VA, et al. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008;83(8):870–9.

    Article  PubMed  CAS  Google Scholar 

  42. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–48.

    Article  PubMed  CAS  Google Scholar 

  43. Fellstrom BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395–407.

    Article  PubMed  CAS  Google Scholar 

  44. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2000;356(9224):147–52.

    Article  PubMed  CAS  Google Scholar 

  45. Harper CR, Jacobson TA. Managing dyslipidemia in chronic kidney disease. J Am Coll Cardiol. 2008;51(25):2375–84.

    Article  PubMed  CAS  Google Scholar 

  46. Bays HE, Goldberg RB, Truitt KE, Jones MR. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med. 2008;168(18):1975–83.

    Article  PubMed  CAS  Google Scholar 

  47. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425–35.

    Article  PubMed  CAS  Google Scholar 

  48. Harris WS. n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr. 1997;65(5 Suppl):1645S–54.

    PubMed  CAS  Google Scholar 

  49. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6A):3C–18.

    Article  PubMed  CAS  Google Scholar 

  50. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse 3rd JR, Leiter LA, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74.

    Article  PubMed  Google Scholar 

  51. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143–21.

    Google Scholar 

  52. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110(2):227–39.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Section of Cardiology, University of Chicago Pritzker School of Medicine, Chicago, IL, 60637, USA

    Matthew J. Sorrentino MD

Authors
  1. Matthew J. Sorrentino MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew J. Sorrentino MD .

Editor information

Editors and Affiliations

  1. Pritzker School of Medicine, Department of Medicine, University of Chicago, S. Maryland Ave. 5841, Chicago, 60637, Illinois, USA

    Matthew J. Sorrentino

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sorrentino, M.J. (2011). Treatment of Dyslipidemia in Patients with Renal Insufficiency and End-Stage Renal Disease. In: Sorrentino, M. (eds) Hyperlipidemia in Primary Care. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-60327-502-6_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-502-6_12

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60327-501-9

  • Online ISBN: 978-1-60327-502-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation